Minetta Liu

Research Collaborator, Professor

Mayo Clinic
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (41)

Purpose: Immune checkpoint blockade (ICB) therapies targeting the PD-1 axis have significantly improved survival in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) and peripheral T-cell receptor (TCR) repertoires are emerging as promising biomarkers for predicting ICB response. Early characterization of ctDNA and TCR dynamics may enable timely treatment adjustments before clinical or radiologic progression. Experimental Design: The IO-KIN study (NCT04606940) is a single-center, prospective trial involving 15 patients with R/M HNSCC treated with nivolumab or pembrolizumab. Blood samples ( n = 104) were collected across seven time points from baseline to day 29. ctDNA was analyzed using a personalized assay (Signatera), and peripheral TCR repertoires were profiled using CapTCR-seq in eight patients. Results: A decline in ctDNA after day 8 was associated with radiologic response, longer progression-free survival, and a trend toward improved overall survival. TCR repertoires transiently diversified between days 8 and 22, with longer diversification windows in patients showing sustained ctDNA decline. Using the GLIPHII algorithm, an Epstein–Barr virus–specific TCR signature was identified and persisted in patients with clinical benefit. Additional TCR signatures, potentially recognizing tumor-associated antigens, emerged as early as day 3 and were linked to positive outcomes. Conclusions: Simultaneous early monitoring of ctDNA and TCR dynamics reveals key determinants of ICB outcomes in R/M HNSCC. The transient nature of TCR diversification emphasizes the importance of precise sample timing to guide early therapeutic decisions and improve patient outcomes.

Year:

2026

PURPOSE Increased heterogeneity in outcomes has been observed postnephrectomy in patients with renal cell carcinoma (RCC), with standard clinical parameters being primarily used for risk assessment. Currently, no blood-based biomarkers are available for molecular residual disease (MRD) detection in RCC. Herein, we performed a multicenter, real-world evaluation of the prognostic value of circulating tumor DNA (ctDNA) in resected RCC. METHODS This real-world evidence-based multi-institutional study included a cohort of 77 patients with stage I-IV RCC. Longitudinal ctDNA testing was performed on plasma samples (n = 295) using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc, Austin, TX). ctDNA results were analyzed, and association with recurrence-free survival was assessed. RESULTS The patient cohort included 77 patients with stage I-IV RCC (clear cell: 64, non–clear cell: 13). Patients who tested ctDNA-positive during the MRD window experienced worse prognosis and a higher likelihood of recurrence (hazard ratios, 18; P < .0001) compared with their ctDNA-negative counterparts. CONCLUSION Overall, we demonstrate the utility of ctDNA testing for MRD detection. Future prospective studies in RCC would be needed to validate the utility of ctDNA in informing clinical decision making.

Year:

2026

ctDNA decrease from C1 to C4 was associated with greater objective response in patients treated with chemoIO at all cutoffs. Number of patients per best objective response with associated increase or decreases in ctDNA between C1 and C4. *Progression-free rate was calculated from the start of therapy rather than the start of C4D1.

Year:

2026

ctDNA decrease from any subsequent cycle was associated with greater objective response in patients treated with chemoIO. Number of patients per best objective response with associated increase or decreases in ctDNA levels between subsequent cycles.

Year:

2026

Biomarker analysis patient cohort characteristics and ITT patient characteristics. Clinical and biomarker characteristics are similar between treatment arms of the biomarker analysis patient cohort evaluated in this study. Clinical and biomarker characteristics are similar between the ITT population in IMpower131 and the biomarker analysis patient cohort evaluated in this study.

Year:

2026

Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after induction. However, there is significant clinical variability in the duration, dosing, and timing of maintenance therapy after induction chemoIO. We used circulating tumor DNA (ctDNA) monitoring to inform outcomes in patients with advanced NSCLC receiving chemoIO. Experimental Design: This retrospective study included 221 patients from a phase III trial of atezolizumab+carboplatin+nab-paclitaxel versus carboplatin+nab-paclitaxel in squamous NSCLC (IMpower131). ctDNA monitoring used the FoundationOne Tracker involving comprehensive genomic profiling of pretreatment tumor tissue, variant selection using an algorithm to exclude nontumor variants, and multiplex PCR of up to 16 variants to detect and quantify ctDNA. Results: ctDNA was detected (ctDNA+) in 96% of pretreatment samples (median, 93 mean tumor molecules/mL), and similar ctDNA dynamics were noted across treatment arms during chemoIO. ctDNA decrease from baseline to C4D1 was associated with improved outcomes across multiple cutoffs for patients treated with chemoIO. When including patients with missing plasma or ctDNA- at baseline, patients with ctDNA- at C4D1 (clearance), had more favorable progression-free survival (median 8.8 vs. 3.5 months; HR, 0.32;0.20–0.52) and OS (median not reached vs. 8.9 months; HR, 0.22; 0.12–0.39) from C4D1 than ctDNA+ patients. Conclusions: ctDNA monitoring during induction chemoIO can inform treatment outcomes in patients with advanced NSCLC. Importantly, monitoring remains feasible and informative for patients missing baseline ctDNA. ctDNA testing during induction chemoIO identifies patients at higher risk for disease progression and may inform patient selection for novel personalized maintenance or second-line treatment strategies.

Year:

2026

Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples ( n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117

Year:

2025

Kaplan–Meier estimates for PFS (A) and OS (B) stratified by ctDNA status post/during ICI treatment. (C) BOR (CR, PR, SD, and PD) stratified based on ctDNA status post/during ICI treatment. In A and B, hazard ratios for PFS and OS have been adjusted for ECOG (0 vs 1/2), p16 status (negative vs positive), and the location of recurrence (locoregional only versus distant metastases). ctDNA: circulating tumor DNA; ICI: immune checkpoint inhibitor; HR: Hazard Ratio; PFS: Progression-free Survival; OS: overall survival; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.

Year:

2025

Purpose: Although immunotherapy improves the overall survival (OS) of patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), only 15% to 20% of patients derive a long-term benefit. We hypothesized that ctDNA kinetics during immunotherapy, with or without chemotherapy, could predict treatment efficacy in patients with R/M SCCHN. Experimental Design: Using a personalized, tumor-informed ctDNA assay, we evaluated ctDNA kinetics from pre- to on-treatment (6–10 weeks after treatment initiation) time points. The primary endpoint was the concordance between ctDNA kinetics and best overall response (BOR). Secondary endpoints were the association of ctDNA clearance and kinetics with OS and progression-free survival (PFS). Results: Of the 41 patients, ctDNA assays were successfully designed for 29, and ctDNA was detected before treatment in 25 patients. ctDNA kinetics was significantly correlated with BOR ( P = 0.00032). Patients with unfavorable ctDNA kinetics had significantly worse PFS compared with those with favorable ctDNA kinetics (HR = 16.98; 95% confidence interval, 3.35–86.1; P = 0.0006). Six patients had ctDNA clearance, all of whom presented a complete or partial response as BOR. PFS and OS were significantly improved in patients with ctDNA clearance compared with those without clearance (PFS: P = 0.0006, OS: P = 0.027). Conclusions: ctDNA kinetics, assessed with a tumor-informed assay, can predict anti–PD-1 therapy efficacy in R/M SCCHN. Early ctDNA clearance during the initial weeks of immunotherapy seems to be a strong predictive marker for a favorable response, as well as improved PFS and OS.

Year:

2025

Relationship between ctDNA kinetics and best overall response (BOR) stratified by immune checkpoint inhibitor type. Stacked bar plots illustrating the distribution of best overall response (BOR: complete response [CR], partial response [PR], stable disease [SD], and progressive disease [PD]) according to ctDNA kinetics (favorable vs. unfavorable) separately for patients treated with nivolumab (n = 8) (A) and pembrolizumab (n = 17) (B). Favorable ctDNA kinetics was defines as >20% of decrease in ctDNA levels; unfavorable ctDNA kinetics included

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (80)

William Huang

Professor (Clinical)

New York University Grossman School of Medicine

UNITED STATES
View details

Samuel Klempner

Associate Professor

Massachusetts General Hospital

UNITED STATES
View details

Thierry André

Sorbonne Université

FRANCE
View details

Aaron R. Hansen

Medical Oncologist

University Health Network

CANADA
View details

Sean Park

Professor

Mayo Clinic Rochester

UNITED STATES
View details

Jianjun Gao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Catherine Alix-Panabières

Director/Professor

University Hospital of Montpellier

FRANCE
View details

Paola Gazzaniga

Sapienza University of Rome

ITALY
View details

Jérôme Galon

Research Director

INSERM

FRANCE
View details

Daniel F. Hayes

Stuart B. Padnos Professor of Breast Cancer Research

University of Michigan Rogel Cancer Center

UNITED STATES
View details

Michail Ignatiadis

Leader Investigator Initiated Trials

Institut Jules Bordet

BELGIUM
View details

Kohei Shigeta

Assistant Professor

Keio University School of Medicine

JAPAN
View details

Takashi Akiyoshi

The Cancer Institute Hospital

JAPAN
View details

Siang-Boon Koh

Academic , Senior Lecturer

University Hospitals Bristol and Weston NHS Foundation Trust

UNITED KINGDOM
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Anna Spreafico

University Health Network

CANADA
View details

Roni Wilke

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel D. Billadeau

-

UNITED STATES
View details

Sanghoon Lee

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Amir Jazaeri

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Adrian V. Lee

University of Pittsburgh

UNITED STATES
View details

Steffi Oesterreich

UPMC Hillman Cancer Center

UNITED STATES
View details

Pamela S. Ohashi

University of Toronto

CANADA
View details

Jeffrey How

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Arnab Basu

The University of Alabama at Birmingham School of Medicine

UNITED STATES
View details

Lillian L. Siu

University Health Network

CANADA
View details

Chetan Bettegowda

Johns Hopkins University School of Medicine

UNITED STATES
View details

Aaron Mansfield

Mayo Clinic Minnesota

UNITED STATES
View details

Leif Ellisen

Professor and Program Director, Breast Oncology

Massachusetts General Hospital

UNITED STATES
View details

Allan Hackshaw

University College London

UNITED KINGDOM
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Yibo Dai

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jean-François Emile

Université de Versailles Saint-Quentin-en-Yvelines

FRANCE
View details

Shannon Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tomasz Michal Beer

Oregon Health & Science University

UNITED STATES
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Jean-Yves Pierga

Head of Department

Institut Curie

FRANCE
View details

Karthik Giridhar

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Tanja Fehm

Professor

University Hospital Düsseldorf

GERMANY
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Haidong Dong

Professor/Consultant

Mayo Clinic Rochester

UNITED STATES
View details

Gwyn Richardson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Leon W. M. M. Terstappen

University of Twente

NETHERLANDS
View details

James Ferguson

Assistant Professor

The University of Alabama

UNITED STATES
View details

Srinivasvinod Saladi

Associate Professor

University of Toledo Medical Center

UNITED STATES
View details

Elisabetta Munzone

Director

European Institute of Oncology

ITALY
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pamela Soliman

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andres Ocampo

Vanderbilt University

UNITED STATES
View details

julien taieb

Professor Head of the department

Université Paris-Saclay

FRANCE
View details

Justin Stebbing

Professor

Imperial College London

UNITED KINGDOM
View details

Michael Gibson

Vanderbilt University Medical Center

UNITED STATES
View details

Evi Lianidou

PROFESSOR

National and Kapodistrian University of Athens

GREECE
View details

Laura Esserman

University of California

UNITED STATES
View details

Cathy Eng

Professor; Associate Director for Strategic Relations and Research Partnerships

Vanderbilt University Medical Center

UNITED STATES
View details

Ying Yuan

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Trevor J. Pugh

Professor

University Health Network

CANADA
View details

Aditya Bardia

UCLA Health

UNITED STATES
View details

Kai Wucherpfennig

Professor and Department Chair

Dana-Farber Cancer Institute

UNITED STATES
View details

Erica Mayer

Dana-Farber Cancer Institute

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

Julia Foldi

Assistant Professor of Medicine

University of Pittsburgh School of Medicine

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

Cédric van Marcke

-

BELGIUM
View details

Klaus Pantel

-

GERMANY
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details

Pierre Laurent-Puig

Université Paris Descartes

FRANCE
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Soroush Rais-Bahrami

The University of Alabama at Birmingham School of Medicine

UNITED STATES
View details

David Boruta

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Markus Wallwiener

University Hospital Heidelberg

GERMANY
View details

DANIELE GENERALI

University of Trieste

ITALY
View details

Kostandinos Sideras

Assistant Professor

Mayo Clinic

UNITED STATES
View details